Erratum: Twins in spirit: DOTATATE and high-affinity DOTATATE (Eur J Nucl Med Mol Imaging (2014)) 41(402) 10.1007/s00259-013-2497-5);Twins in spirit: DOTATATE and high-affinity DOTATATE

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 11, 2013, Pages 1789-

  Brogsitter, Claudia ^a   Schottelius, Margret ^b   Zöphel, Klaus ^a   Kotzerke, Jörg ^a   Wester, Hans Jürgen ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; RADIOPHARMACEUTICAL AGENT;

AGED; CASE REPORT; DRUG UPTAKE; HUMAN; LIVER METASTASIS; MIDGUT; NEUROENDOCRINE TUMOR; NOTE;

AGED; HUMANS; LIVER NEOPLASMS; MALE; ORGANOMETALLIC COMPOUNDS;

EID: 84885421514     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2557-x     Document Type: Erratum

References (3)

1. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242-4.
2. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Horsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-16.
3. Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M, et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol. 2006;13:1081-90.